Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Gilead Sciences, Inc.    GILD

News SummaryMost relevantAll newsSector news 
The feature you requested does not exist. However, we suggest the following feature:

Gilead Sciences, Inc. (NASDAQ:GILD) Begins A Process That Could Alleviate Its Problems

share with twitter share with LinkedIn share with facebook
share via e-mail
12/01/2016 | 02:44pm CET

Gilead Sciences, Inc. (NASDAQ:GILD) has switched course and has begun aggressive marketing of its HIV drug Truvada as a preventative medicine for HIV-negative healthy people. The company initially struggled with conflicting views of pitching Truvada for PrEP (pre-exposure prophylaxis).

Some patient activists argued that promoting Truvada as a preventative drug for HIV would encourage unsafe practices and cause promiscuity to flourish. Those concerns caused Gilead to go slow on spreading Truvada’s PrEP message. But the company also started facing pressure from other activists who reasoned that staying mum on the PrEP capabilities of Truvada was bad for people who needed help from the drug, such as those who share needles.

After listening to both sides of the arguments, Gilead has come to the conclusion that it is important to lift the lid on Truvada’s preventative properties. Pitching Truvada for PrEP would not only save many Americans from catching HIV, but also unlock a revenue opportunity for Gilead.

Addressable market

As per CDC estimates some 1.2 million people in the U.S. are at high risk of being infected by HIV. If that is the case, then the sales opportunity for Truvada in preventative market is significant.

The uptake of Truvada for PrEP is gaining momentum rapidly since Gilead started getting the word out broadly.  Gilead first targeted doctors with Truvada for PrEP promotions through advertisements on professional publications and digital channels. Then it expanded the outreach to include the homosexual community. Lately it is pitching to patients and the response has been sizable, especially given that Gilead has a patient assistance program that helped keep the cost of the medicine low.

From about 60,000 people who used Truvada for PrEP earlier this year, as of the end of 3Q16 the drug was used by 90,000 people for that purpose in the U.S. alone.

“We expect PrEP to continue to be a significant part of Gilead’s growth in HIV going forward, particularly in the U.S.,” said Gilead COO Kevin Young.

Gilead wants Truvada for PrEP to catch on quickly considering that the company is already struggling with weak sales in its hepatitis C mainstay. Sales of Sovaldi and Harvoni have slowed down amid competition in the hepatitis C space and protests over the high costs of the drugs.

Gilead stock is down about 27% YTD and down more than 31% over the last one year.

The post Gilead Sciences, Inc. (NASDAQ:GILD) Begins A Process That Could Alleviate Its Problems appeared first on Market Exclusive.

© Market Exclusive 2016, source Market Exclusive

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on GILEAD SCIENCES, INC.
12/01 GILEAD SCIENCES, INC. (NASDAQ : GILD) Begins A Process That Could Alleviate Its ..
11/29 GILEAD SCIENCES, INC. (NASDAQ : GILD) Takes Lead Against AbbVie Inc (NYSE:ABBV) ..
11/28 Global Hepatitis C Drug Market - Merck & Co, Kenilworth, Roche, Basel GlaxoSm..
11/23 MATINAS BIOPHARMA HOLDINGS INC. (OTC : MTNB) Can Take A $350M Antifungal Market ..
11/23 GILEAD SCIENCES : Canada, Inc., is awarded prestigious Prix Galien Canada Innova..
11/22 GILEAD SCIENCES : to Present at the Annual Piper Jaffray Healthcare Conference o..
11/22 GILEAD SCIENCES : Announces Top-Line Results From Two Phase 3 Studies Evaluating..
11/22 GILEAD SCIENCES : Announces Promotion of James R. Meyers to Executive Vice Presi..
11/22 GILEAD SCIENCES : European CHMP Adopts Positive Opinion for Gilead's Vemlidy® Te..
11/17 GILEAD SCIENCES : Patent Issued for Solid Forms of Tenofovir (USPTO 9487546)
More news
Sector news : Bio Therapeutic Drugs
12/03DJJOHNSON & JOHNSON : Boosts Actelion Bid -Bloomberg
12/02 Pharma execs weigh in on possible changes under Trump
11/30 ACTELION : Rejecting J&J could leave Actelion with 'lot of explaining to do'
11/28 Actelion's ambitious independent-minded CEO will drive up takeover price
11/26DJWHAT'S NEWS : Business & Finance -- WSJ
More sector news : Bio Therapeutic Drugs
News from SeekingAlpha
09:24a Gilead Just Not Living Up To Expectations
08:22a What Could Pfizer Do With Cash From A Tax Holiday
12/05 Precision AML Trial Adds Pharma Candidates To The Mix
12/05 INCYTE : Another Celgene?
Financials ($)
Sales 2016 30 175 M
EBIT 2016 20 022 M
Net income 2016 13 955 M
Debt 2016 1 855 M
Yield 2016 2,57%
P/E ratio 2016 6,96
P/E ratio 2017 6,94
EV / Sales 2016 3,22x
EV / Sales 2017 3,35x
Capitalization 95 331 M
More Financials
Duration : Period :
Gilead Sciences, Inc. Technical Analysis Chart | GILD | US3755581036 | 4-Traders
Full-screen chart
Technical analysis trends GILEAD SCIENCES, ...
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 28
Average target price 97,4 $
Spread / Average Target 35%
Consensus details
EPS Revisions
More Estimates Revisions
John F. Milligan President, Chief Executive Officer & Director
John C. Martin Executive Chairman
Kevin B. Young Chief Operating Officer
Robin L. Washington Chief Financial Officer & Executive Vice President
Norbert W. Bischofberger Chief Scientific Officer & Executive VP-Research
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
GILEAD SCIENCES, INC.-28.43%95 331
AMGEN, INC.-11.29%108 084
ACTELION LTD45.20%21 671
More Results